#MedChem
LightNews LightNews
rscmedchem.rsc.org
🔓Be sure to read #OpenAccess research from Jonathan D. Sellars & co. @newcastleuni.bsky.social in our latest issue describing the synthesis and antimycobacterial evaluation of novel 3,5-dinitrobenzoyl substituted amino acid hydrazides #medchem

Find it in full here🔽
doi.org/10.1039/d6md...
November 6, 2026 at 1:04 PM
pharmadigest.net
Drug discovery digest, Nov 7 — 30 new articles:
• Novartis tallies nine tumor reports among Zolgensma recipients, two tied to vector integration

#DrugDiscovery #MedChem #ChemSky #BioSky #Biotech
Daily digest — 2026-11-07 | The Pharma Digest
Today's 30 items: 10 medchem (DCAF16 degraders, a brain-penetrant caspase-2 inhibitor), 5 pharmacology (VRC01 breakthrough resistance), 8 computational (benchmark and docking caveats), and 7 industry stories led by AstraZeneca's reported Rhythm bid and the Zolgensma tumor reports.
pharmadigest.net
November 6, 2026 at 7:43 PM
rubenragg.bsky.social
We are hiring and are looking for a Deputy Editor for ChemBioChem & Chem. Eur. J. If you have a PhD in medchem, chembio, or a related field and love science beyond the bench, this is for you. Please like and share!

wiley.wd1.myworkdayjobs.com/wiley_career...

@chemistryeurope.bsky.social
Deputy Editor, Chemistry
We believe in bold ideas, diverse perspectives, and the drive to transform knowledge into impact. Here, your curiosity fuels progress, your voice shapes innovation, and your ambition helps redefine wh...
wiley.wd1.myworkdayjobs.com
November 6, 2026 at 2:57 PM
pharmadigest.net
Drug discovery digest, Nov 5 — 31 new articles:
• Compass to Complete COMP360 FDA Filing Within Two Weeks as Usona Files First
• XT1061, an optimized HBV capsid assembly modulator, advances through Phase I

#DrugDiscovery #MedChem #ChemSky #BioSky #Biotech
Daily digest — 2026-11-05 | The Pharma Digest
Tonight's digest has 31 articles: 7 medchem, 9 pharmacology, 8 computational and 7 industry. Highlights include AbbVie's up-to-$1.47B gut-targeted EP4 IBD licence, Compass's imminent COMP360 FDA filing, and Servier's sevasemten Phase 2 miss.
pharmadigest.net
November 5, 2026 at 12:48 PM
orgbiomolchem.rsc.org
🔓Be sure to read this #OpenAccess paper by Alan M. Jones et al. from @unibirmingham.bsky.social in our latest issue on the late-stage electrosynthesis of sulfoxide metabolites from phenothiazine-based antipsychotic drugs #orgchem #medchem

Find it on our website👇
doi.org/10.1039/d6ob...
November 6, 2026 at 12:02 PM
pharmadigest.net
Drug discovery digest, Nov 8 — 27 new articles:
• FDA Gives J&J's Rybrevant Faspro Accelerated Approval in Head and Neck Cancer
• Live-cell chemoproteomics yields a brain-penetrant covalent PIKfyve inhibitor with durable target occupancy

#DrugDiscovery #MedChem #ChemSky #BioSky #Biotech
Daily digest — 2026-11-08 | The Pharma Digest
Tonight's digest has 27 items: six medchem, and seven each in pharmacology, computational and industry. Highlights include a brain-penetrant covalent PIKfyve inhibitor, the first PCNA-directed PET tracer, J&J's Rybrevant approval in head and neck cancer, and CMS's 340B payment cut.
pharmadigest.net
November 8, 2026 at 12:48 PM
pharmadigest.net
Drug discovery digest, Nov 6 — 27 new articles:
• Boehringer Takes Options on Six Preclinical Oncology Programs from Sino Biopharm's Subsidiaries, Worth Up to $7B
• First small molecule found to block coronavirus M-N protein interaction

#DrugDiscovery #MedChem #ChemSky #BioSky #Biotech
Daily digest — 2026-11-06 | The Pharma Digest
Today's digest has 27 items: seven each from medchem, computational and industry, six from pharmacology. Highlights: Sanofi dropping Nurix's STAT6 degrader, Boehringer's up-to-$7B Sino Biopharm options, and a reality check on diffusion-guided MD sampling.
pharmadigest.net
November 6, 2026 at 12:49 PM
medchem1.bsky.social
“Alzheimer’s is a disease in which we desperately need new thoughts, new ideas, people thinking differently. And we’re definitely contributing that.”

Dr. Weaver reflects on the experiences that have shaped his research approach. 🧠

www.soci.org/chemistry-an...

#Alzheimers #DrugDiscovery #MedChem
Donald Weaver, SCI Canada Medal winner: ‘Sooner or later, the breakthrough is going to come’
Donald Weaver still remembers the day that defined the rest of his career, setting him on the path to working in drug research as a chemist.
www.soci.org
November 6, 2026 at 6:32 PM
pharmadigest.net
Drug discovery digest, Nov 4 — 30 new articles:
• Merck KGaA to leave contract manufacturing, selling five US sites to Lonza
• Oral bis-macrocycle RMC-0708 targets active KRAS Q61H via tri-complex

#DrugDiscovery #MedChem #ChemSky #BioSky #Biotech
Daily digest — 2026-11-04 | The Pharma Digest
Today's digest carries 30 items across all four sections. Medchem is led by two oral KRAS tri-complex inhibitors; computational work benchmarks free-energy engines and AlphaFold3 nanobody prediction; industry highlights are Lonza's purchase of Merck KGaA's US CDMO sites and Karyopharm's Chapter 11 filing.
pharmadigest.net
November 4, 2026 at 12:49 PM
rscmedchem.rsc.org
🔓Check out #OpenAccess research by Šárka Štěpánková, Martin Krátký et al. @charlesuni.cuni.cz reporting the synthesis of rhodanine and 2,4-dioxothiazolidine-based amides as dual-action cholinesterase inhibitors and antioxidants #medchem

Read their full report here🔽
doi.org/10.1039/d6md...
November 2, 2026 at 11:45 AM
pwk2024.bsky.social
A most excellent molecule with which to conclude the week #SynChem #BB #MedChem #DrugDesign #DrugDiscovery #cheminformatics #chemsky 🧪
enaminestore.com/catalog/EN30...
October 30, 2026 at 4:28 PM
iocbprague.bsky.social
🤝 Representatives from IOCB Prague’s management, research teams and IOCB Tech visited Gilead Sciences (USA) to discuss ongoing scientific collaboration...

🧵

#IOCB #IOCBPrague #medchem
November 2, 2026 at 2:35 PM
rscmedchem.rsc.org
Don't miss in our latest issue this review by Ahmed M. Almehdi, Sameh S. M. Soliman et al. from the University of Sharjah discussing the potential of purine nucleoside phosphorylase as a therapeutic target in cancer #medchem

Check it out in full on our website👇
doi.org/10.1039/d6md...
November 4, 2026 at 12:15 PM
pharmadigest.net
Drug discovery digest, Nov 3 — 30 new articles:
• FDA accepts uniQure's Huntington's gene therapy AMT-130 for priority review, May 1 action date
• Cereblon molecular glues are widening their reach to protein kinases

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-11-03 | The Pharma Digest
Tonight's 30 items run from cereblon glues, HDAC3 PROTACs and covalent DEL hits in medchem to sceptical computational reads on docking reproducibility and virtual-screening hits that fail resynthesis. In industry, uniQure's AMT-130 priority review and the ivonescimab combination race lead.
pharmadigest.net
November 2, 2026 at 9:57 PM
pharmadigest.net
Drug discovery digest, Nov 2 — 27 new articles:
• Gilead's Kite Pauses Two KITE-753 Lymphoma Trials After Severe Neurotoxicity Cases
• First-in-class METTL1 inhibitor STM9005 shows that blocking tRNA methylation can curb diverse cancers in mice

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-11-02 | The Pharma Digest
Today's digest has 27 articles: 8 medchem, 8 pharmacology, 9 computational and 2 industry. Highlights include a first-in-class METTL1 inhibitor in Nature, audits showing leakage can inflate AI ADMET and peptide-prediction claims, and a partial clinical hold on Kite's KITE-753 CAR-T trials.
pharmadigest.net
November 2, 2026 at 1:09 PM
rscmedchem.rsc.org
🔓Take a look in our latest issue at a #OpenAccess paper from @dirktrauner.bsky.social & co. describing the optimization of CRBN-ligands for optical targeted protein degradation #medchem

📍 @upenn.edu
doi.org/10.1039/d6md...
October 30, 2026 at 3:29 PM
pharmadigest.net
Drug discovery digest, Oct 31 — 28 new articles:
• Dren Bio raises $350M oversubscribed round to advance CD94 antibody toward registration
• Click chemistry switches on lung-targeted protein degradation only where the nanoparticles have landed

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-10-31 | The Pharma Digest
Today's digest has 28 items: ten medchem, eight pharmacology, two computational and eight industry. Highlights include click-activated degraders aimed at the lung, MERTK blockade against fibrosis, Ono's five Phase 2 misses and Dren Bio's $350M round.
pharmadigest.net
October 31, 2026 at 12:48 PM
fabermdphd.bsky.social
2. No direct measureable affinity between lead compound and ALK - many companies would have killed the project then but thankfully they kept pushing!

3. Also initial hit didn't degrade the target in cells - could have also killed the project!

#medchem

2/2
October 31, 2026 at 1:33 PM
pharmadigest.net
Drug discovery digest, Nov 1 — 21 new articles:
• AbbVie Beats Again on Skyrizi, Rinvoq and Neuroscience and Signals Bolt-Ons, Not Another Allergan
• KRAS G12D inhibitor INCB161734: from oral tool compound to clinic

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-11-01 | The Pharma Digest
Today's digest has 21 items: Science Translational Medicine work on Treg-depleting CCR8 engagers and synNotch CAR T, KRAS G12D and KEAP1–NRF2 chemistry, and Q3 reads from Sanofi, Regeneron, AbbVie and Alnylam. Computational coverage is a single toxicity-benchmark preprint.
pharmadigest.net
November 1, 2026 at 12:48 PM
orgbiomolchem.rsc.org
📢Our latest issue is now online!

🔓Check out the #OpenAccess paper behind the cover from David H. Sherman, @pereiralab.bsky.social & co. @umich.edu describing the chemoselective halogenation of premarineosin A for next-generation antimalarial development #orgchem #medchem

doi.org/10.1039/d6ob...
October 28, 2026 at 3:25 PM
pharmadigest.net
Drug discovery digest, Oct 30 — 23 new articles:
• Genmab's Petosemtamab Plus Keytruda Wins Early in First-Line Head and Neck Phase 3
• Inhaled sGC stimulator frespaciguat designed for lung-selective action in PH-COPD

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-10-30 | The Pharma Digest
Today's digest has 23 items: eight each in medicinal chemistry and pharmacology, seven in industry. Highlights include a light-switchable β1-adrenoceptor agonist, an inhaled sGC stimulator for PH-COPD, Genmab's Phase 3 interim win and Novartis's $1.9B Avidity write-down.
pharmadigest.net
October 30, 2026 at 12:50 PM
pharmadigest.net
Drug discovery digest, Oct 29 — 19 new articles:
• Lilly's Retatrutide Tops Ozempic Head-to-Head in Type 2 Diabetes
• VHL-based PROTACs turn a pan-FGFR inhibitor into FGFR2/4-selective degraders

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-10-29 | The Pharma Digest
Tonight's digest has 19 items across medchem, pharmacology and industry; computational had no entries. Chemistry runs from FGFR2/4 PROTACs to MCT1 and ALDH1B1 inhibitors, pharmacology from M4 PAM mechanism to CYP metabolism, and the news is led by Lilly's retatrutide head-to-head win and the Takeda/Innovent Claudin 18.2 ADC.
pharmadigest.net
October 29, 2026 at 12:49 PM
martinstoermer.bsky.social
I kept my organic and Medchem books. Even my long-outdated 2nd?3rd? Edition March (the yellow hardback). Haven’t opened it in >15 years. But I keep it because it was the first serious hard core organic text I bought
October 27, 2026 at 6:07 PM
pharmadigest.net
Drug discovery digest, Oct 28 — 21 new articles:
• Incyte's G12D Inhibitor Posts 89% Response With FOLFIRINOX in Pancreatic Cancer
• Cell-penetrating peptide conjugation broadens and strengthens lasso peptide antibiotics

#DrugDiscovery #MedChem #Pharma #Biotech
Daily digest — 2026-10-28 | The Pharma Digest
Tonight's digest has 21 items across medchem, pharmacology and industry: covalent and peptide chemistry, ML models for safety assessment, and ESMO readouts led by Merck/Kelun's sac-TMT survival win and Incyte's G12D inhibitor. Artiva's wind-down and Ferring's Gameto deal also stand out.
pharmadigest.net
October 28, 2026 at 12:56 PM
ao0909.bsky.social
I gave TypeSafe's Jev and 6 LLMs 106 medicinal-chemistry questions. On general ADME rules Jev scored 94% (LLMs 88–100%); on choosing between close analogs it scored 61% (top LLMs 77–86%). All 36 answers with confidence ≥0.9 were correct. #MedChem
aurio9923.com/en/2026/10/2...
Testing Jev on Medicinal Chemistry Knowledge | ADME General Rules and Specific Compounds, Compared with Six LLMs
A technical note comparing Jev and six LLMs on 106 medicinal-chemistry questions: accuracy by question type.
aurio9923.com
October 28, 2026 at 3:49 PM